Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moupali Das

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Pediatrics|April 22, 2021
Compassionate Use of Remdesivir in Children With Severe COVID-19David L Goldman, Margaret L Aldrich, Stefan H F Hagmann, et al.
The Lancet. HIV|July 13, 2026
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trialLinda-Gail Bekker, Dhayendre Moodley, Dazon Dixon Diallo, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
JAMA|October 24, 2013
Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trialLisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2024
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global StudiesRaphael J Landovitz, Li Tao, Juan Yang, et al.
JAMA|July 13, 2016
Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical TrialLisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
The New England Journal of Medicine|July 24, 2024
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda-Gail Bekker, Moupali Das, Quarraisha Abdool Karim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2020
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Pediatrics|April 22, 2021
Compassionate Use of Remdesivir in Children With Severe COVID-19David L Goldman, Margaret L Aldrich, Stefan H F Hagmann, et al.
The Lancet. HIV|July 13, 2026
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trialLinda-Gail Bekker, Dhayendre Moodley, Dazon Dixon Diallo, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
JAMA|October 24, 2013
Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trialLisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2024
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global StudiesRaphael J Landovitz, Li Tao, Juan Yang, et al.
JAMA|July 13, 2016
Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical TrialLisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
The New England Journal of Medicine|July 24, 2024
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda-Gail Bekker, Moupali Das, Quarraisha Abdool Karim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2020
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, et al.
Pageof 7